- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Syncor subsidiary acquires Radpharm Scientific
An Australian subsidiary of Syncor has acquired Radpharm Scientific, distributor and manufacturer of diagnostic radiopharmaceuticals. Based in Canberra, Radpharm distributes its products to more than 160 nuclear medicine practices in Australia and
An Australian subsidiary of Syncor has acquired Radpharm Scientific, distributor and manufacturer of diagnostic radiopharmaceuticals. Based in Canberra, Radpharm distributes its products to more than 160 nuclear medicine practices in Australia and exports to New Zealand, Singapore, Malaysia, Thailand, and Hong Kong. The acquisition gives Syncor a presence in Canberra along with its existing sites in Sydney, Perth, and Brisbane.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
